Ocular Therapeutix has begun enrolling patients in its phase 3 SOL-R clinical trial, which will evaluate the efficacy of Axpaxli (previously called OTX-TKI), a novel axitinib intravitreal implant, in treating wet age-related macular degeneration (AMD). The trial will compare the 6-month dosing of Axpaxli against the current standard of care, 2 mg aflibercept administered every 8 weeks.

The global study will enroll approximately 825 patients and features a third arm to ensure proper masking by including 8 mg aflibercept (Eylea HD) dosed every 6 months. The SOL-R trial aims to provide crucial insights into the long-term efficacy and safety of repeat Axpaxli dosing, particularly in real-world clinical settings.